Internal Medicine, Pulmonary Disease · Hartford, CT
NPI
1023112596
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
85 Seymour St, Suite 923
Hartford, CT, 06106
Phone (860) 247-1876
Groups this clinician bills Medicare through
Medicare paid, 2024
$70K
1,121 services
Medicare patients, 2024
351
Average age 79
Drug cost, 2024
$2.7M
4,565 prescriptions
Company payments, 2025
$3,885
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John Russomanno was code 99214 (office e&m - established), 384 times for 229 patients. In total John Russomanno billed 1,121 services in 23 codes, and Medicare paid $70K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-02-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 384 | 229 | $96.42 | $37K |
| 94010 Pulmonary Function Testing | Office | 225 | 205 | $21.80 | $4,906 |
| 94729 Pulmonary Function Testing | Office | 65 | 63 | $44.54 | $2,895 |
| 94727 Pulmonary Function Testing | Office | 62 | 60 | $35.47 | $2,199 |
| 99213 Office E&M - Established | Office | 60 | 54 | $61.61 | $3,697 |
| 99204 Office E&M - New | Office | 59 | 59 | $129.37 | $7,633 |
| 94060 Pulmonary Function Testing | Office | 42 | 41 | $30.00 | $1,260 |
| 94664 E&M - Miscellaneous | Office | 27 | 27 | $14.28 | $386 |
| 99306 SNF E&M | Facility | 24 | 23 | $148.31 | $3,559 |
| 99215 Office E&M - Established | Office | 21 | 19 | $142.45 | $2,991 |
By year: 2022 $145K for 1,501 services; 2023 $86K for 1,057 services; 2024 $70K for 1,121 services.
Medicare prescription drug claims, 2024
In 2024, the drug John Russomanno prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 1,321 prescriptions and refills. In total John Russomanno wrote 4,565 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 1,321 | 1,709 | 295 | $1.1M |
| Albuterol Sulfate Hfa Albuterol Sulfate | 746 | 885 | 320 | $18K |
| Montelukast Sodium Generic | 497 | 1,313 | 136 | $6,318 |
| Prednisone Generic | 286 | 324 | 158 | $1,142 |
| Breo Ellipta Fluticasone/Vilanterol | 229 | 338 | 47 | $136K |
| Arnuity Ellipta Fluticasone Furoate | 164 | 246 | 47 | $61K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 119 | 157 | 29 | $14K |
| Fluticasone Propionate Generic | 84 | 188 | 37 | $1,866 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 83 | 107 | 20 | $65K |
| Ventolin Hfa Albuterol Sulfate | 72 | 78 | 28 | $4,583 |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 63 | 101 | 18 | $47K |
| Azithromycin Generic | 62 | 77 | 39 | $233 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 61 | 75 | 15 | $11K |
| Symbicort Budesonide/Formoterol Fumarate | 61 | 67 | 14 | $16K |
| Ofev Nintedanib Esylate | 57 | 57 | Under 11 | $737K |
Brand drugs: 2,881 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John Russomanno $3,885 ($3,885 in general payments such as food, travel and fees) from 21 companies. The largest payer was GlaxoSmithKline, LLC. with $1,102.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 71 | $1,102 |
| AstraZeneca Pharmaceuticals LP AZN | 27 | $636 |
| Verona Pharma, Inc. VRNA | 12 | $285 |
| Viatris Specialty LLC | 15 | $284 |
| Regeneron Healthcare Solutions, Inc. REGN | 12 | $231 |
| Harmony Biosciences LLC HRMY | 7 | $230 |
| Amgen Inc. AMGN | 9 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 7 | $173 |
| Actelion Pharmaceuticals US, Inc. JNJ | 7 | $164 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $103 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.